Tyme Technologies Inc (NASDAQ:TYME) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 7,830,000 shares, a growth of 16.3% from the January 15th total of 6,730,000 shares. Currently, 19.0% of the shares of the stock are short sold. Based on an average trading volume of 511,300 shares, the days-to-cover ratio is currently 15.3 days.
Shares of NASDAQ TYME traded up $0.03 during mid-day trading on Friday, reaching $1.28. The company had a trading volume of 4,625 shares, compared to its average volume of 660,677. The stock has a market cap of $156.01 million, a PE ratio of -5.27 and a beta of 0.40. The company has a 50-day moving average price of $1.51 and a two-hundred day moving average price of $1.30. Tyme Technologies has a 1-year low of $0.92 and a 1-year high of $3.42.
A number of analysts recently commented on TYME shares. HC Wainwright reiterated a “buy” rating and issued a $9.50 target price on shares of Tyme Technologies in a report on Thursday, February 6th. Zacks Investment Research cut shares of Tyme Technologies from a “buy” rating to a “hold” rating in a report on Saturday, January 11th.
Several institutional investors have recently made changes to their positions in TYME. Renaissance Technologies LLC purchased a new stake in shares of Tyme Technologies during the fourth quarter valued at $25,000. Citigroup Inc. increased its stake in Tyme Technologies by 72.2% in the 4th quarter. Citigroup Inc. now owns 23,556 shares of the company’s stock worth $33,000 after purchasing an additional 9,873 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Tyme Technologies by 31.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 42,232 shares of the company’s stock worth $59,000 after purchasing an additional 10,124 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Tyme Technologies during the 3rd quarter worth about $71,000. Finally, Barclays PLC raised its holdings in Tyme Technologies by 102.1% during the 4th quarter. Barclays PLC now owns 59,040 shares of the company’s stock worth $83,000 after buying an additional 29,821 shares during the period. 12.92% of the stock is currently owned by institutional investors.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
See Also: Options Trading – What is a Straddle?
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.